Alien Registration- Cote, Andre (Lewiston, Androscoggin County)

https://digitalmaine.com/alien_docs/29243/thumbnail.jp

Alien Registration- Cote, Andre J. (Sanford, York County)

https://digitalmaine.com/alien_docs/3137/thumbnail.jp

The ACS Virgo Cluster Survey. XIII. SBF Distance Catalog and the Three-Dimensional Structure of the Virgo Cluster

The ACS Virgo Cluster Survey consists of HST ACS imaging for 100 early-type galaxies in the Virgo Cluster, observed in the F475W and F850LP filters. We derive distances for 84 of these galaxies using the method of surface brightness fluctuations (SBFs), present the SBF distance catalog, and use this database to examine the three-dimensional distribution of early-type galaxies in the Virgo Cluster. The SBF distance moduli have a mean (random) measurement error of 0.07 mag (0.5 Mpc), or roughly 3 times better than previous SBF measurements for Virgo Cluster galaxies. Five galaxies lie at a distance of ~23 Mpc and are members of the W' cloud. The remaining 79 galaxies have a narrow distribution around our adopted mean distance of 16.5+/-0.1 (random mean error) +/-1.1 Mpc (systematic). The rms distance scatter of this sample is 0.6+/-0.1 Mpc, with little dependence on morphological type or luminosity class (i.e., 0.7+/-0.1 and 0.5+/-0.1 Mpc for the giants and dwarfs, respectively). The back-to-front depth of the cluster measured from our sample of galaxies is 2.4+/-0.4 Mpc (i.e., +/-2sigma of the intrinsic distance distribution). The M87 (cluster A) and M49 (cluster B) subclusters are found to lie at distances of 16.7+/-0.2 and 16.4+/-0.2 Mpc, respectively. There may be a third subcluster associated with M86. A weak correlation between velocity and line-of-sight distance may be a faint echo of the cluster velocity distribution not having yet completely virialized. In three dimensions, Virgo's early-type galaxies appear to define a slightly triaxial distribution, with axis ratios of (1:0.7:0.5). The principal axis of the best-fit ellipsoid is inclined ~20-40 deg. from the line of sight, while the galaxies belonging to the W' cloud lie on an axis inclined by ~10-15 deg.Comment: 21 pages, 21 postscript figures. Also available at http://www1.cadc-ccda.hia-iha.nrc-cnrc.gc.ca/community/ACSVCS/index.htm

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention

The EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway plays prominent roles in malignant transformation, prevention of apoptosis, drug resistance and metastasis. The expression of this pathway is frequently altered in breast cancer due to mutations at or aberrant expression of: HER2, ERalpha, BRCA1, BRCA2, EGFR1, PIK3CA, PTEN, TP53, RB as well as other oncogenes and tumor suppressor genes. In some breast cancer cases, mutations at certain components of this pathway (e.g., PIK3CA) are associated with a better prognosis than breast cancers lacking these mutations. The expression of this pathway and upstream HER2 has been associated with breast cancer initiating cells (CICs) and in some cases resistance to treatment. The anti-diabetes drug metformin can suppress the growth of breast CICs and herceptin-resistant HER2+ cells. This review will discuss the importance of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway primarily in breast cancer but will also include relevant examples from other cancer types. The targeting of this pathway will be discussed as well as clinical trials with novel small molecule inhibitors. The targeting of the hormone receptor, HER2 and EGFR1 in breast cancer will be reviewed in association with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway.USAMRMC {[}BC022276]; Intramural RECDA Award; Italian Association for Cancer Research (AIRC); MIUR-PRIN; Italian MIUR-FIRB Accordi di Programma; Italian ``Ministero dell'Istruzione, dell'Universita e della Ricerca (Ministry for Education, Universities and Research) - FIRB-MERIT {[}RBNE08YYBM]; Italian Ministry of Economy and Finance; Italian Ministry of Health, Ricerca Finalizzata Stemness; MIUR FIRB {[}RBAP11ZJFA\_001]; CRO; Italian Association for Cancer Research, (AIRC) (RM PI); Italian Association for Cancer Research, (AIRC) {[}MCO10016]; Italian Ministry of Health; Regione Friuli Venezia-Giuli

Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery

Background For patients undergoing noncardiac surgery, bleeding and hypotension are frequent and associated with increased mortality and cardiovascular complications. Tranexamic acid (TXA) is an antifibrinolytic agent with the potential to reduce surgical bleeding; however, there is uncertainty about its efficacy and safety in noncardiac surgery. Although usual perioperative care is commonly consistent with a hypertension-avoidance strategy (i.e., most patients continue their antihypertensive medications throughout the perioperative period and intraoperative mean arterial pressures of 60 mmHg are commonly accepted), a hypotension-avoidance strategy may improve perioperative outcomes. Methods The PeriOperative Ischemic Evaluation (POISE)-3 Trial is a large international randomized controlled trial designed to determine if TXA is superior to placebo for the composite outcome of life-threatening, major, and critical organ bleeding, and non-inferior to placebo for the occurrence of major arterial and venous thrombotic events, at 30 days after randomization. Using a partial factorial design, POISE-3 will additionally determine the effect of a hypotension-avoidance strategy versus a hypertension-avoidance strategy on the risk of major cardiovascular events, at 30 days after randomization. The target sample size is 10,000 participants. Patients ≥45 years of age undergoing noncardiac surgery, with or at risk of cardiovascular and bleeding complications, are randomized to receive a TXA 1 g intravenous bolus or matching placebo at the start and at the end of surgery. Patients, health care providers, data collectors, outcome adjudicators, and investigators are blinded to the treatment allocation. Patients on ≥ 1 chronic antihypertensive medication are also randomized to either of the two blood pressure management strategies, which differ in the management of patient antihypertensive medications on the morning of surgery and on the first 2 days after surgery, and in the target mean arterial pressure during surgery. Outcome adjudicators are blinded to the blood pressure treatment allocation. Patients are followed up at 30 days and 1 year after randomization. Discussion Bleeding and hypotension in noncardiac surgery are common and have a substantial impact on patient prognosis. The POISE-3 trial will evaluate two interventions to determine their impact on bleeding, cardiovascular complications, and mortality. Trial registration ClinicalTrials.gov NCT03505723. Registered on 23 April 2018

Alien Registration- Cote, Andre (Lewiston, Androscoggin County)

https://digitalmaine.com/alien_docs/29243/thumbnail.jp